Total Payments
$114,873
2024 Payments
$30,174
Companies
17
Transactions
143
Medicare Patients
11
Medicare Billing
$2,799
Payment Breakdown by Category
Consulting$44,585 (38.8%)
Travel$35,181 (30.6%)
Research$23,035 (20.1%)
Other$7,044 (6.1%)
Food & Beverage$3,954 (3.4%)
Education$1,074 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $44,585 | 16 | 38.8% |
| Travel and Lodging | $35,181 | 34 | 30.6% |
| Unspecified | $23,035 | 22 | 20.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,044 | 11 | 5.3% |
| Food and Beverage | $3,954 | 56 | 3.4% |
| Education | $1,074 | 2 | 0.9% |
| Honoraria | $1,000 | 2 | 0.9% |
Payments by Type
General
$91,838
121 transactions
Research
$23,035
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $74,519 | 58 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,375 | 17 | $0 (2024) |
| Genentech, Inc. | $6,494 | 8 | $0 (2022) |
| Roche Products Limited | $6,462 | 10 | $0 (2022) |
| Heron Therapeutics, Inc. | $5,330 | 5 | $0 (2017) |
| Exact Sciences Corporation | $5,198 | 6 | $0 (2023) |
| Celgene Corporation | $2,459 | 6 | $0 (2017) |
| TerSera Therapeutics LLC | $2,095 | 2 | $0 (2024) |
| Daiichi Sankyo Inc. | $1,982 | 11 | $0 (2023) |
| Genentech USA, Inc. | $1,160 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,174 | 14 | F. Hoffmann-La Roche AG ($27,741) |
| 2023 | $13,892 | 18 | F. Hoffmann-La Roche AG ($8,550) |
| 2022 | $19,448 | 20 | AstraZeneca Pharmaceuticals LP ($6,244) |
| 2021 | $8,822 | 6 | F. Hoffmann-La Roche AG ($8,322) |
| 2020 | $5,257 | 8 | F. Hoffmann-La Roche AG ($4,745) |
| 2019 | $16,152 | 37 | F. Hoffmann-La Roche AG ($13,234) |
| 2018 | $12,397 | 21 | F. Hoffmann-La Roche AG ($9,815) |
| 2017 | $8,730 | 19 | Heron Therapeutics, Inc. ($5,330) |
All Payment Transactions
143 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $2,159.82 | Research |
| Study: T DM1 high risk EBC pts with residual inv disease • Category: BioOncology | ||||||
| 12/10/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Consulting Fee | Cash or cash equivalent | $1,330.00 | General |
| Category: BioOncology | ||||||
| 12/06/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $760.00 | General |
| 10/23/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $95.00 | General |
| Category: Oncology | ||||||
| 05/14/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $12,160.00 | General |
| 05/14/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $10,722.20 | General |
| 05/14/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $413.94 | General |
| 05/14/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $99.09 | General |
| 05/14/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $58.30 | General |
| 05/14/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $37.72 | General |
| 05/07/2024 | Menarini Silicon Biosystems, Inc. | Cellsearch (Device) | Food and Beverage | Cash or cash equivalent | $129.17 | General |
| Category: Diagnostics | ||||||
| 05/02/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $117.37 | General |
| Category: Oncology | ||||||
| 02/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $91.29 | General |
| 12/31/2023 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $1,662.62 | Research |
| Study: T DM1 high risk EBC pts with residual inv disease • Category: BioOncology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $542.55 | Research |
| Study: T DM1 high risk EBC pts with residual inv disease • Category: BioOncology | ||||||
| 12/08/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $760.00 | General |
| 12/08/2023 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $38.00 | General |
| 10/11/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Consulting Fee | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 10/11/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Travel and Lodging | In-kind items and services | $296.67 | General |
| Category: Oncology | ||||||
| 10/04/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $120.19 | General |
| Category: Oncology | ||||||
| 09/06/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Travel and Lodging | In-kind items and services | $725.99 | General |
| Category: Oncology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $1,456.85 | Research |
| Study: T DM1 high risk EBC pts with residual inv disease • Category: BioOncology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $312.47 | Research |
| Study: Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $282.75 | Research |
| Study: Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| T DM1 high risk EBC pts with residual inv disease | F. Hoffmann-La Roche AG | $7,797 | 6 |
| RISK-BASED DECISION-MAKING IN THE TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER RECOMMENDATIONS BASED ON THE CURRENT STATE OF KNOWLEDGE | F. Hoffmann-La Roche AG | $5,270 | 1 |
| A Randomized, Multicenter, Open-Label Phase III Study to Evaluate Efficacy and Safety of Trastuzumab Emtansine vs Trastuzumab as Adjuvant Therapy for Patients with HER2 Primary Breast Cancer with Residual Tumor Present Pathologically in Breast or Axillary Lymph Nodes Following Preoperative Therapy | F. Hoffmann-La Roche AG | $4,745 | 6 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III STUDY TO EVALUATE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2 PRIMARY BREAST CANCER WITH RESIDUAL TUMOR PRESENT PATHOLOGICALLY IN BREAST OR AXILLARY LYMPH NODES FOLLOWING PREOPERATIVE THERAPY | F. Hoffmann-La Roche AG | $2,450 | 3 |
| A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GDC-9545 COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER | F. Hoffmann-La Roche AG | $2,178 | 4 |
| Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | F. Hoffmann-La Roche AG | $595.22 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 11 | 27 | $8,478 | $2,799 |
Total Patients
11
Total Services
27
Medicare Billing
$2,799
Procedure Codes
1
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 27 | $8,478 | $2,799 | 33.0% |
About Dr. Charles Geyer, MD
Dr. Charles Geyer, MD is a Internal Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1891795001.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Geyer, MD has received a total of $114,873 in payments from pharmaceutical and medical device companies, with $30,174 received in 2024. These payments were reported across 143 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($44,585).
As a Medicare-enrolled provider, Geyer has provided services to 11 Medicare beneficiaries, totaling 27 services with total Medicare billing of $2,799. Data is available for 1 year (2021–2021), covering 1 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Houston, TX
- Active Since 07/29/2005
- Last Updated 06/23/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1891795001
Products in Payments
- Kadcyla (Biological) $38,285
- CINVANTI (Drug) $5,330
- Perjeta (Biological) $5,270
- Cologuard Collection Kit (Device) $5,198
- Abraxane (Drug) $2,459
- Zoladex (Drug) $2,095
- Enhertu (Drug) $1,926
- Herceptin (Biological) $1,780
- Tecentriq (Biological) $1,330
- Non-Covered Product (Drug) $1,285
- Oral Paclitaxel (Drug) $500.00
- ENHERTU (Biological) $433.81
- VERZENIO (Drug) $145.55
- Cellsearch (Device) $129.17
- Trodelvy (Drug) $111.26
- ENHERTU (Drug) $56.38
- IBRANCE (Drug) $11.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Houston
Stephen Pappas, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Mohamed Othman, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Aung Naing, Md, MD
Internal Medicine — Payments: $925,146
Internal Medicine $925,146
Miguel Escobar, M.d, M.D
Internal Medicine — Payments: $924,228
Internal Medicine $924,228
Dr. Christie Ballantyne, Md, MD
Internal Medicine — Payments: $815,154
Internal Medicine $815,154
John Heymach, M.d, M.D
Internal Medicine — Payments: $786,947
Internal Medicine $786,947